Merck Reports Earnings Exceeding Expectations, Yet Stock Declines.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy MRK?
Source: Barron's
- Earnings Report: Merck reported better-than-expected earnings for the fourth quarter.
- Stock Performance: Despite the positive earnings, Merck's stock declined due to concerns over its 2026 forecast.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 121.660
Low
95.00
Averages
119.53
High
139.00
Current: 121.660
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck's Enflonsia Shows Efficacy in RSV Treatment for Infants
- Clinical Trial Results: Merck's Enflonsia demonstrated safety and efficacy in a phase 3 trial for respiratory syncytial virus (RSV) treatment, particularly in high-risk infants and children under two, indicating its potential for the second RSV season.
- SMART Trial Data: Data from the SMART trial revealed that monoclonal antibody (mAb) serum concentrations in high-risk children and infants treated with Enflonsia were comparable to those in healthy infants from a pivotal trial, underscoring the drug's effectiveness and safety.
- High-Risk Population: Nearly all participants in the SMART trial had chronic lung disease or congenital heart disease, suggesting that Enflonsia could provide essential protection for these vulnerable groups, with a potential need for an additional dose during the second RSV season.
- Researcher Insights: Paolo Manzoni, an investigator for the SMART trial, noted that these new findings highlight Enflonsia's potential to protect high-risk children, emphasizing the drug's significance in RSV treatment.
See More
Merck Reports Positive Results from RSV Trial
- Positive Trial Progress: Merck presented positive results from the Phase 3 SMART trial at the RSVVW Conference, indicating that Enflonsia's safety profile in children under 2 is consistent with previous studies, potentially providing additional protection for high-risk children and likely facilitating FDA's expanded indication approval.
- Clinical Data Support: The latest data from the SMART trial shows that monoclonal antibody concentrations of Enflonsia are similar to those in healthy infants from earlier studies, suggesting its potential effectiveness in the second RSV season, further solidifying its prospects for FDA approval in 2025.
- Strong Market Performance: Merck's stock is currently trading at $121.62, 5.9% above its 20-day simple moving average and has increased by 42.13% over the past 12 months, indicating robust market performance and proximity to 52-week highs.
- Optimistic Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $119.95, and Guggenheim has raised its target to $140.00, reflecting analysts' confidence in its future performance.
See More
Merck Reports Positive Phase 3 Results for RSV Treatment ENFLONSIA
- Positive Trial Results: Merck's Phase 3 SMART trial for ENFLONSIA (clesrovimab) in high-risk infants and children reported positive outcomes, indicating consistent safety during the second RSV season compared to the first, suggesting potential efficacy in this demographic.
- Safety Consistency: The safety profile observed in children under 2 years receiving ENFLONSIA aligns with that seen in the MK-1654-007 trial, reinforcing confidence in the drug's application for high-risk pediatric patients.
- Similar Antibody Concentrations: The monoclonal antibody serum concentrations in high-risk children under 2 years were comparable to those in healthy infants from the pivotal Phase 2b/3 CLEVER trial, indicating ENFLONSIA's potential effectiveness in this vulnerable population.
- Efficacy Extrapolation Support: Results from the SMART study support the extrapolation of ENFLONSIA's efficacy to children under 2 years at increased risk for severe RSV disease, enhancing Merck's competitive position in the RSV treatment market and laying a foundation for future clinical applications.
See More
Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in RSV Prevention
- Positive Trial Results: Merck presented findings from the Phase 3 SMART trial of ENFLONSIA (clesrovimab) at the RSVVW’26 conference in Rome, indicating consistent safety and efficacy in high-risk children, supporting global regulatory submissions.
- Safety Consistency: In the second RSV season, adverse reactions such as injection site erythema and fever were comparable to the first season, confirming the drug's safety profile in vulnerable populations and suggesting potential for additional protection.
- Efficacy Support: Results from the SMART trial demonstrated that a single dose of ENFLONSIA provides up to five months of protection in high-risk children, with a 3.0% RSV-related hospitalization rate in the second season, highlighting its preventive potential against severe RSV disease.
- Global Regulatory Submission: Merck plans to share the second season results with the FDA and global regulatory authorities to seek an expanded indication for ENFLONSIA in high-risk children, further solidifying its critical role in RSV prevention.
See More
Merck's ENFLONSIA Shows Promising Results in RSV Treatment
- Clinical Trial Results: At the 9th RSVVW Conference, Merck announced positive findings for ENFLONSIA (clesrovimab) during the second RSV season, demonstrating consistent safety and efficacy in high-risk infants, supporting global regulatory submissions.
- Safety Analysis: In the second RSV season, adverse reactions such as injection site erythema and fever were low among children receiving ENFLONSIA, indicating good safety in vulnerable populations and potential for additional protection.
- Serum Concentration Comparison: The serum concentrations of ENFLONSIA in high-risk children were similar to those in healthy infants from the pivotal CLEVER trial, further validating its potential in preventing severe RSV disease and supporting future treatment options.
- Market Outlook: Merck aims to expand ENFLONSIA's availability to all eligible high-risk children globally, with FDA approval anticipated in 2025, marking a significant advancement in RSV prevention efforts.
See More
FDA Grants Breakthrough Therapy Designation for Rybrevant
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy Designation for Rybrevant (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma, applicable to patients with recurrent or metastatic disease after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, indicating strong recognition and market potential for the new therapy.
- Contract Extension: The collaboration agreement signed by Johnson & Johnson in January 2025 has been extended to mid-2026 under the same economic terms, including a fixed monthly management fee, driven by strong engagement and satisfaction metrics, reflecting ongoing confidence in the program's performance.
- Market Model Development: Trellus Health CEO Marla Dubinsky stated that the company is establishing a scalable go-to-market model for pharmaceuticals, focusing on disciplined execution, recurring revenue growth, and expansion in immunology and inflammation, showcasing a positive outlook for future developments.
- Financial Outlook: Trellus Health expects fiscal 2025 revenue to be approximately $545,000 and has reduced its monthly cash burn to around $400,000, demonstrating improved financial management and confidence in future growth prospects.
See More
Merck's Enflonsia Shows Efficacy in RSV Treatment for Infants
- Clinical Trial Results: Merck's Enflonsia demonstrated safety and efficacy in a phase 3 trial for respiratory syncytial virus (RSV) treatment, particularly in high-risk infants and children under two, indicating its potential for the second RSV season.
- SMART Trial Data: Data from the SMART trial revealed that monoclonal antibody (mAb) serum concentrations in high-risk children and infants treated with Enflonsia were comparable to those in healthy infants from a pivotal trial, underscoring the drug's effectiveness and safety.
- High-Risk Population: Nearly all participants in the SMART trial had chronic lung disease or congenital heart disease, suggesting that Enflonsia could provide essential protection for these vulnerable groups, with a potential need for an additional dose during the second RSV season.
- Researcher Insights: Paolo Manzoni, an investigator for the SMART trial, noted that these new findings highlight Enflonsia's potential to protect high-risk children, emphasizing the drug's significance in RSV treatment.
See More
Merck Reports Positive Results from RSV Trial
- Positive Trial Progress: Merck presented positive results from the Phase 3 SMART trial at the RSVVW Conference, indicating that Enflonsia's safety profile in children under 2 is consistent with previous studies, potentially providing additional protection for high-risk children and likely facilitating FDA's expanded indication approval.
- Clinical Data Support: The latest data from the SMART trial shows that monoclonal antibody concentrations of Enflonsia are similar to those in healthy infants from earlier studies, suggesting its potential effectiveness in the second RSV season, further solidifying its prospects for FDA approval in 2025.
- Strong Market Performance: Merck's stock is currently trading at $121.62, 5.9% above its 20-day simple moving average and has increased by 42.13% over the past 12 months, indicating robust market performance and proximity to 52-week highs.
- Optimistic Analyst Ratings: The stock carries a 'Buy' rating with an average price target of $119.95, and Guggenheim has raised its target to $140.00, reflecting analysts' confidence in its future performance.
See More
Merck Reports Positive Phase 3 Results for RSV Treatment ENFLONSIA
- Positive Trial Results: Merck's Phase 3 SMART trial for ENFLONSIA (clesrovimab) in high-risk infants and children reported positive outcomes, indicating consistent safety during the second RSV season compared to the first, suggesting potential efficacy in this demographic.
- Safety Consistency: The safety profile observed in children under 2 years receiving ENFLONSIA aligns with that seen in the MK-1654-007 trial, reinforcing confidence in the drug's application for high-risk pediatric patients.
- Similar Antibody Concentrations: The monoclonal antibody serum concentrations in high-risk children under 2 years were comparable to those in healthy infants from the pivotal Phase 2b/3 CLEVER trial, indicating ENFLONSIA's potential effectiveness in this vulnerable population.
- Efficacy Extrapolation Support: Results from the SMART study support the extrapolation of ENFLONSIA's efficacy to children under 2 years at increased risk for severe RSV disease, enhancing Merck's competitive position in the RSV treatment market and laying a foundation for future clinical applications.
See More
Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in RSV Prevention
- Positive Trial Results: Merck presented findings from the Phase 3 SMART trial of ENFLONSIA (clesrovimab) at the RSVVW’26 conference in Rome, indicating consistent safety and efficacy in high-risk children, supporting global regulatory submissions.
- Safety Consistency: In the second RSV season, adverse reactions such as injection site erythema and fever were comparable to the first season, confirming the drug's safety profile in vulnerable populations and suggesting potential for additional protection.
- Efficacy Support: Results from the SMART trial demonstrated that a single dose of ENFLONSIA provides up to five months of protection in high-risk children, with a 3.0% RSV-related hospitalization rate in the second season, highlighting its preventive potential against severe RSV disease.
- Global Regulatory Submission: Merck plans to share the second season results with the FDA and global regulatory authorities to seek an expanded indication for ENFLONSIA in high-risk children, further solidifying its critical role in RSV prevention.
See More
Merck's ENFLONSIA Shows Promising Results in RSV Treatment
- Clinical Trial Results: At the 9th RSVVW Conference, Merck announced positive findings for ENFLONSIA (clesrovimab) during the second RSV season, demonstrating consistent safety and efficacy in high-risk infants, supporting global regulatory submissions.
- Safety Analysis: In the second RSV season, adverse reactions such as injection site erythema and fever were low among children receiving ENFLONSIA, indicating good safety in vulnerable populations and potential for additional protection.
- Serum Concentration Comparison: The serum concentrations of ENFLONSIA in high-risk children were similar to those in healthy infants from the pivotal CLEVER trial, further validating its potential in preventing severe RSV disease and supporting future treatment options.
- Market Outlook: Merck aims to expand ENFLONSIA's availability to all eligible high-risk children globally, with FDA approval anticipated in 2025, marking a significant advancement in RSV prevention efforts.
See More
FDA Grants Breakthrough Therapy Designation for Rybrevant
- Breakthrough Therapy Designation: The FDA has granted Breakthrough Therapy Designation for Rybrevant (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced head and neck squamous cell carcinoma, applicable to patients with recurrent or metastatic disease after progression on platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor, indicating strong recognition and market potential for the new therapy.
- Contract Extension: The collaboration agreement signed by Johnson & Johnson in January 2025 has been extended to mid-2026 under the same economic terms, including a fixed monthly management fee, driven by strong engagement and satisfaction metrics, reflecting ongoing confidence in the program's performance.
- Market Model Development: Trellus Health CEO Marla Dubinsky stated that the company is establishing a scalable go-to-market model for pharmaceuticals, focusing on disciplined execution, recurring revenue growth, and expansion in immunology and inflammation, showcasing a positive outlook for future developments.
- Financial Outlook: Trellus Health expects fiscal 2025 revenue to be approximately $545,000 and has reduced its monthly cash burn to around $400,000, demonstrating improved financial management and confidence in future growth prospects.
See More
